Trial NCT04927936
Publication Sablerolles R, N Engl J Med, 2022
Primary outcome on the report: SARS-CoV-2-specific binding antibodies at day 0 and 28 days after the boost

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.